Activity of the growth hormone/insulin-like growth factor-I axis in critically ill children

Journal of Pediatric Endocrinology and Metabolism

Volumn 18, Issue 4, 2005, Pages 363-372

  Gardelis, John G ^a,b   Hatzis, Tassos D ^a   Stamogiannou, Lela N ^a   Dona, Artemis A ^a   Fotinou, Aspasia D ^a   Brestas, Paraskevas S ^a   Constantopoulos, Adreas G ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

Critical illness; Growth hormone; IGF binding protein 1; IGF binding protein 3; IGF II; Insulin like growth factor (IGF) I; Sepsis; Trauma

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ARTICLE; CHEMOLUMINESCENCE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CRITICAL ILLNESS; FEMALE; GROWTH HORMONE BLOOD LEVEL; HORMONE ACTION; HORMONE DETERMINATION; HORMONE RESISTANCE; HUMAN; IMMUNORADIOMETRIC ASSAY; INJURY; INTENSIVE CARE; MALE; MORTALITY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SEPSIS;

EID: 17144411886     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2005.18.4.363     Document Type: Article

References (49)

1. Wilmore DW. Catabolic illness. N Engl J Med 1991; 325: 695-702.
2. Jenkins RC, Ross RJM. The endocrinology of the critically ill. Curr Opin Endocrinol 1996; 3: 138-145.
3. Van den Berghe G, de Zegher F. Anterior pituitary function during critical illness and dopamine treatment. Crit Care Med 1996; 24: 1580-1590.
4. Faber J, Kirkegaard C, Ramsmussen B, Westh H, Busch-Sorensen M, Jensen IW. Pituitary-thyroid axis in critical illness. J Clin Endocrinol Metab 1987; 65: 315-320.
5. Wojnar MM, Fan J, Frost RA, Gelato MC, Lang CH. Alterations in the insulin-like growth factor system in trauma patients. Am J Physiol 1995; 268: R970-977.
6. Weekers F, Van den Berghe G. Endocrine modifications and interventions during critical illness. Proc Nutr Soc 2004; 63: 443-450.
7. Nylen ES, Muller B. Endocrine changes in critical illness. J Intens Care Med 2004; 19: 67-82.
8. Dahn MS, Lange MP, Jacobs LA. Insulin-like growth factor-I production is inhibited in human sepsis. Arch Surg 1988; 123: 1409-1414.
9. Timmins AC, Cotterill AM, Hughes SC, Holly JM, Ross RJ, Blum W, Hinds CJ. Critical illness is associated with low circulating concentrations of insulin-like growth factors -I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease. Crit Care Med 1996; 24: 1460-1466.
10. Beeton CA, Brooks RA, Chatfield D, Human M, Rushton N. Circulating levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in patients with severe head injury. J Bone Joint Surg (Br) 2002; 84: 434-439.
11. Baxter RC, Hawker FH, To C, Stewart PM, Homan SR. Thirty-day monitoring of insulin-like growth factors and their binding proteins in intensive care unit patients. Growth Horm IGF Res 1998; 8: 455-463.
12. Voerman HJ, van Schijndel RJM, Groeneveld ABJ, de Boer H, Nauta JP, van der Veen EA, Thijs LG. Effects of recombinant human growth hormone in patients with severe sepsis. Ann Surg 1992; 216: 648-651.
13. Ross RJM, Chew SL. Acquired growth hormone resistance. Eur J Endocrinol 1995; 132: 655-660.
14. Thissen JP, Underwood LE, Ketelslegers JM. Regulation of insulin-like growth factor-I in starvation and injury. Nutr Rev 1999; 57: 167-176.
15. Jenkins R, Ross R. Acquired growth hormone resistance in adults. Baillières Clin Endocrinol Metab 1998; 12: 315-329.
16. Thissen JP, Ketelsleger JM, Underwood LE. Nutritional regulation of insulin-like growth factors. Endocr Rev 1994; 15: 80-85.
17. Bentham J, Rodriguez-Arnao J, Ross RJ. Acquired growth hormone resistance in patients with hypercatabolism. Horm Res 1993; 40: 87-91.
18. Ross RJM, Miell J, Freeman E, Jones J, Matthews D, Preece M, Buchanan C. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. Clin Endocrinol (Oxf) 1991; 35: 47-54.
19. Van den Berghe G, de Zegher F, Lauwers P, Veldhuis JD. Growth hormone secretion in critical illness: effect of dopamine. J Clin Endocrinol Metab 1994; 79: 1141-1146.
20. Gianotti L, Broglio F, Aimaretti G, Arvat E, Colombo S, Di Summa M, Gallioli G, Pittoni G, Sardo E, Stella M, Zanello M, Miola C, Ghigo E. Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions. J Endocrinol Invest 1998; 21: 115-121.
21. Pittoni G, Gallioli G, Zanello M, Gianotti L, Bogher MF, Colombo S, Broglio F, Santoro C, Davia G, Papini MG, Destefanis S, Minuto F, Miola C, Ghigo E. Activity of GH/IGF-I axis in trauma and septic patients during artificial nutrition: Different behavior patterns? J Endocrinol Invest 2002; 25: 214-223.
22. Casanueva FF, Villanueva L, Dieguez C, Diaz Y, Cabranes JA, Szoke B, Scanlon MF, Schally AV, Fernandez-Cruz A. Free fatty acids block growth hormone (GH) releasing hormone-stimulated GH secretion in man directly at the pituitary. J Clin Endocrinol Metab 1987; 65: 634-642.
23. Voerman HJ, Strack van Schijndel RJM, de Boer H, van der Veen EA, Thijs LG. Growth hormone: secretion and administration in catabolic adult patients, with emphasis on the critically ill patient. Neth J Med 1992; 41: 229-244.
24. Haymond MW, Mauras N. The rationale for use of recombinant human growth hormone and insulin-like growth factor-I for catabolic conditions in humans. Horm Res 1996; 46: 202-207.
25. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341: 785-792.
26. Carroll PV. Treatment with growth hormone and insulin-like growth factor-I in critical illness. Best Pract Res Clin Endocrinol Metab 2001; 15: 435-451.
27. Botfield C, Ross RJ, Hinds CJ. The role of IGFs in catab,ilism. Baillières Clin Endocrinol Metab 1997; 11: 679-697.
28. Joosten KF, de Kleijn ED, Westerterp M, de Hoog M, Eijck FC, Hop WCJ, Voort EV Hazelzet JA, Hokken-Koelega AC. Endocrine and metabolic responses in children with meningococcal sepsis: striking differences between survivors and nonsurvivors. J Clin Endocrinol Metab 2000; 85: 3746-3753.
29. de Groof F, Joosten KF, Janssen JA, de Kleijn ED, Hazelzet JA, Hop WC, Uitterlinden P, van Doom J, Hokken-Koelega AC. Acute stress response in children with meningococcal sepsis: important differences in the growth hormone/insulin-like growth factor-I axis between nonsurvivors and survivors. J Clin Endocrinol Metab 2002; 87: 3118-3124.
30. Pollack MM, Ruttimann UE, Getson PR. Pediatric risk of mortality (PRISM) score. Crit Care Med 1988; 16: 110-1116.
31. Cole TJ. The LMS method for constructing normalized growth standards. Eur J Clin Nutr 1990; 44: 45-60.
32. Jones J, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
33. Froesch ER, Zenobi PD, Hussain M. Metabolic and therapeutic effects of insulin-like growth factor I. Horm Res 1994; 42: 66-71.
34. Donahue SP, Phillips LS. Response of IGF-I to nutritional support in malnourished hospital patients: a possible indicator of short-term changes in nutritional status. Am J Clin Nutr 1989; 50: 962-969.
35. Defalque D, Brandt N, Ketelslegers JM, Thissen JP. GH insensitivity induced by endotoxin injection is associated with decreased liver GH receptors. Am J Physiol 1999; 276: 565-572.
36. Wolf M, Bohm S, Brand M, Kremann G, Proinflammatory cytokines interleukin 1β and tumor necrosis factor α inhibit growth hormone stimulation of insulin-like growth factor I synthesis and growth hormone receptor mRNA levels in cultured rat liver cells. Eur J Endocrinol 1996; 135: 729-737.
37. Imura H, Fuketa J, Mori T. Cytokines and endocrine function: an interaction between the immune and neuroendocrine systems. Clin Endocrinol (Oxf) 1991; 35: 107-115.
38. Blackwell TS, Christman JW. Sepsis and cytokines: current status. Br J Anaesth 1996; 77: 110-117.
39. Lee PD, Giudice LC, Conover CA, Powell DR. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med 1997; 216: 319-357.
40. Samstein B, Hoimes ML, Fan J, Frost RA, Gelato MC, Lang CH. IL-6 stimulation of insulin-like growth factor binding protein (IGFBP)-1 production. Biochem Biophys Res Commun 1996; 228: 611-615.
41. Delhanty PJ, Baxter RC. The regulation of acid-labile subunit gene expression and secretion by cyclic adenosine 3′,5′-monophosphate. Endocrinology 1998; 139: 260-265.
42. Van den Berghe G. Growth hormone secretagogues in critical illness. Horm Res 1999; 51: 21-28.
43. Van den Berghe G. Endocrine evaluation of patients with critical illness. Endocrinol Metab Clin North Am 2003; 32: 385-410.
44. Voerman HJ, Strack van Schijndel RJ, Groeneveld AB. Pulsatile hormone secretion during severe sepsis: accuracy of different blood sampling regimens. Metabolism 1992; 41: 934-940.
45. Frayn KN, Price DA, Maycock PF, Carroll SM. Plasma somatomedin activity after injury in man and its relationship to other hormonal and metabolic changes. Clin Endocrinol (Oxf) 1984; 20: 179-187.
46. Briard N, Dadoum F, Pommier G, Sauze N, Lebouc Y, Oliver C, Dutour A. IGF-I/IGFBPs system response to endotoxin challenge in sheep. J Endocrinol 2000; 164: 361-369.
47. Umpleby AM, Carroll PV, Russell-Jones DL, Treacher DF, Jackson NC. Glutamine supplementation and GH/IGF-I treatment in critically ill patients: effect on glutamine metabolism and protein balance. Nutrition 2002; 18: 127-129.
48. Carroll PV, Jackson NC, Russell-Jones DL, Treacher DF, Sonksen P, Umpleby AM. Combined growth hormone/insulin-like growth factor I in addition to glutamine-supplemented TPN results in net protein anabolism in critical illness. Am J Physiol Endocrinol Metab 2004; 286: E151-157.
49. Weekers F, Michalaki M, Coopmans W, Van Herck E, Veldhuis JD, Darras VM, Van den Berghe G. Endocrine and metabolic effects of growth hormone (GH) compared with GH-releasing peptide, thyrotropin-releasing hormone, and insulin infusion in a rabbit model of prolonged critical illness. Endocrinology 2004; 145: 205-213.